ACT Biotech Release: Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity

Published: Jan 20, 2011

SAN FRANCISCO, Jan. 20, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent. These data were presented at the eighth annual ASCO 2011 Gastrointestinal Cancer Symposium that is taking place on January 20-22, 2011, in San Francisco, CA.

Back to news